Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

In 2017, an autologous chimeric antigen receptor (CAR) T cell therapy indicated for children and young adults with relapsed and/or refractory CD19(+) acute lymphoblastic leukaemia became the first gene therapy to be approved in the USA. This innovative form of cellular immunotherapy has been associa...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahadeo, Kris M., Khazal, Sajad J., Abdel-Azim, Hisham, Fitzgerald, Julie C., Taraseviciute, Agne, Bollard, Catherine M., Tewari, Priti, Duncan, Christine, Traube, Chani, McCall, David, Steiner, Marie E., Cheifetz, Ira M., Lehmann, Leslie E., Mejia, Rodrigo, Slopis, John M., Bajwa, Rajinder, Kebriaei, Partow, Martin, Paul L., Moffet, Jerelyn, McArthur, Jennifer, Petropoulos, Demetrios, O’Hanlon Curry, Joan, Featherston, Sarah, Foglesong, Jessica, Shoberu, Basirat, Gulbis, Alison, Mireles, Maria E., Hafemeister, Lisa, Nguyen, Cathy, Kapoor, Neena, Rezvani, Katayoun, Neelapu, Sattva S., Shpall, Elizabeth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Consensus Statement
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096894/
https://www.ncbi.nlm.nih.gov/pubmed/30082906
http://dx.doi.org/10.1038/s41571-018-0075-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096894/
https://www.ncbi.nlm.nih.gov/pubmed/30082906
http://dx.doi.org/10.1038/s41571-018-0075-2

Ejemplares similares